FDA, U. (2018) “Risco potencial de defeitos congênitos do tubo neural com dolutegravir”, Farmacoterapêutica, 22(03), pp. 10–16. Available at: https://revistas.cff.org.br/farmacoterapeutica/article/view/2451 (Accessed: 1 September 2024).